Matinas BioPharma Holdings, Inc.
Matinas BioPharma Holdings, Inc., a prominent player in the pharmaceutical preparation manufacturing industry, is headquartered in the United States. Founded in 2013, the company has made significant strides in developing innovative lipid-based drug delivery systems, particularly for the treatment of infectious diseases and other serious health conditions.
Matinas BioPharma is renowned for its unique core product, the MAT9001, which leverages its proprietary lipid nanocrystal technology to enhance the bioavailability of therapeutic agents. This innovative approach positions the company at the forefront of the pharmaceutical sector, addressing critical needs in drug delivery.
With a commitment to advancing healthcare solutions, Matinas BioPharma has achieved notable milestones, including strategic partnerships and successful clinical trials, solidifying its market position as a leader in pharmaceutical innovation.
-20 vs industry average
Matinas BioPharma Holdings, Inc.’s score of 18 is lower than 26% of the industry. This can give you a sense of how well the company is doing compared to its peers.
Part of the Sustainability team at Matinas BioPharma Holdings, Inc.?
- Control how your company's emission story is told
- Respond to customers efficiently
- See who's viewing your profile
Industry Intensity
Pharmaceutical Preparation Manufacturing has below-average carbon intensity
Industry performance
The Pharmaceutical Preparation Manufacturing industry has reduced its overall emissions by 19% since 0
Emissions trajectory 2020 – 2025
Reported emissions
Scope 3 accounts for ••• of total emissions.
Matinas BioPharma Holdings, Inc.'s reported carbon emissions
Matinas BioPharma Holdings, Inc., headquartered in the US and operating in the Pharmaceutical Preparation Manufacturing industry, reported approximately 686,600 kg CO2e for its Scope 1 and Scope 2 emissions in 2022. For 2021, the company disclosed Scope 1 emissions totalling approximately 533,000,000 kg CO2e. Scope 3 emissions data was not available for either reporting year, with "purchased goods and services" identified as a missing data point. Matinas BioPharma Holdings, Inc. has not publicly disclosed specific greenhouse gas reduction targets or commitments, nor is it participating in initiatives like the Science Based Targets initiative (SBTi) or the Climate Pledge based on the provided information. The company's climate data is not cascaded from a parent organisation.
Unlock detailed emission data
Access structured emission data, company specific factors and auditable source documents
Matinas BioPharma Holdings, Inc.’s Climate Goals (2030 & 2050)
No climate goals have been disclosed for Matinas BioPharma Holdings, Inc. yet.
Scope 3 top emissions categories
No scope 3 category breakdown has been disclosed yet.
Emissions comparison with industry peers
View similar organisations
Matinas BioPharma Holdings, Inc.
Usage policy
You’re welcome to quote or reference data from this page, but please include a visible link back to this URL. Bulk collection, resale, or redistribution of data from multiple profiles is not permitted.
See our License Agreement for more details.
Where does DitchCarbondata come from?
Discover our data-driven methodology for measuring corporate climate action and benchmarking against industry peers
Learn moreCurious to see your top suppliers emissions?
Book a demo for a pilot project